Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01651325 · ClinicalTrials.gov registry record · Phase 1

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

A Phase 1 study of Pharmacokinetics of Isavuconazole and Healthy Adult Volunteers, sponsored by Astellas Pharma Global Development.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT01651325 is a Phase 1 study of Pharmacokinetics of Isavuconazole and Healthy Adult Volunteers that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 24 participants, below the 58-participant average among 4 other Pharmacokinetics of Isavuconazole trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01651325, a Phase 1 study of Pharmacokinetics of Isavuconazole and Healthy Adult Volunteers, has completed, sponsored by Astellas Pharma Global Development.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of dextromethorphan in healthy adult subjects.

Interventions

  • DRUG Isavuconazole
  • DRUG dextromethorphan

Study Locations (1)

Maryland

  • Parexel - Baltimore

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2012-05
Est. Completion 2012-05
Phase Phase 1

Sponsor

Astellas Pharma Global Development

168 total trials

What the Registry Record Tells You About NCT01651325

The ClinicalTrials.gov registry entry for NCT01651325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 4 other Pharmacokinetics of Isavuconazole trials with a reported enrollment target (59% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pharmacokinetics of Isavuconazole appearing as the primary indexed condition, and to 2 interventions - of which Isavuconazole is the first listed.

NCT01651325 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01651325 about?

NCT01651325 is a clinical study titled "Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects". The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of dextromethorphan in healthy adult subjects.

What is the current status of trial NCT01651325?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2012-05. Estimated completion is 2012-05.

What conditions does trial NCT01651325 study?

This clinical trial studies the following conditions: Pharmacokinetics of Isavuconazole, Healthy Adult Volunteers, Pharmacokinetics of Dextromethorphan.

What interventions are being tested in trial NCT01651325?

The interventions under investigation include: Isavuconazole (DRUG), dextromethorphan (DRUG).

Who is sponsoring clinical trial NCT01651325?

This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01651325 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pharmacokinetics of Isavuconazole

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.